- Home
- MU vs VRTX Comparison
MU vs VRTX Comparison
Compare MU & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MU
- VRTX
- Stock Information
- Founded
- MU 1978
- VRTX 1989
- Country
- MU United States
- VRTX United States
- Employees
- MU N/A
- VRTX N/A
- Industry
- MU Semiconductors
- VRTX EDP Services
- Sector
- MU Technology
- VRTX Technology
- Exchange
- MU Nasdaq
- VRTX Nasdaq
- Market Cap
- MU 107.9B
- VRTX 119.6B
- IPO Year
- MU N/A
- VRTX 1991
- Fundamental
- Price
- MU $90.12
- VRTX $397.27
- Analyst Decision
- MU Strong Buy
- VRTX Buy
- Analyst Count
- MU 25
- VRTX 30
- Target Price
- MU $137.33
- VRTX $513.68
- AVG Volume (30 Days)
- MU 27.3M
- VRTX 1.8M
- Earning Date
- MU 12-18-2024
- VRTX 02-03-2025
- Dividend Yield
- MU 0.51%
- VRTX N/A
- EPS Growth
- MU N/A
- VRTX N/A
- EPS
- MU 3.46
- VRTX N/A
- Revenue
- MU $29,094,000,000.00
- VRTX $10,625,800,000.00
- Revenue This Year
- MU $56.03
- VRTX $12.54
- Revenue Next Year
- MU $20.93
- VRTX $8.52
- P/E Ratio
- MU $26.04
- VRTX N/A
- Revenue Growth
- MU 79.80
- VRTX 10.06
- 52 Week Low
- MU $79.15
- VRTX $377.85
- 52 Week High
- MU $157.54
- VRTX $519.88
- Technical
- Relative Strength Index (RSI)
- MU 39.08
- VRTX 24.08
- Support Level
- MU $97.76
- VRTX $377.85
- Resistance Level
- MU $112.04
- VRTX $474.19
- Average True Range (ATR)
- MU 4.95
- VRTX 12.72
- MACD
- MU -0.98
- VRTX -6.53
- Stochastic Oscillator
- MU 23.09
- VRTX 19.69
About MU Micron Technology Inc.
Micron is one of the largest semiconductor companies in the world, specializing in memory and storage chips. Its primary revenue stream comes from dynamic random access memory, or DRAM, and it also has minority exposure to not-and or NAND, flash chips. Micron serves a global customer base, selling chips into data centers, mobile phones, consumer electronics, and industrial and automotive applications. The firm is vertically integrated.
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.